Perspectives on drugs: Hepatitis C treatment for injecting drug users. by unknown
PERSPECTIVES ON DRUGS 
Hepatitis C treatment  
for injecting drug users
I  A hidden epidemic of hepatitis C
Hepatitis C is the most common infectious disease in people 
who inject drugs, among whom it is usually transmitted 
through the sharing of injecting equipment such as needles 
and syringes. Most of those who become infected go on to 
develop chronic HCV infection, which can lead to severe 
health problems in individuals and place a major burden 
on health care systems. Yet hepatitis C is both preventable 
and curable, and the development of new medicines to 
treat hepatitis C, has made rapid progress with several new 
medications obtaining marketing authorization in 2014 and 
2015.
Hepatitis C virus (HCV) infection is highly prevalent among 
people who inject drugs across Europe, with national infection 
levels for this group ranging from 14 % to 84 %. However, 
infected individuals often show no noticeable symptoms, and 
many are unaware that they are carrying the virus, leading to 
it being referred to as a ‘hidden’ epidemic. People who inject 
opioids in Europe constitute an ageing population, which 
includes many who have been living with hepatitis C for 15 
to 25 years. The natural history of chronic hepatitis C virus 
infection (cirrhosis risk escalates after 15 to 20 years) and 
the ageing cohort effect in this population mean that a large 
burden of advanced liver disease can be expected over the 
next decade. 
I  Reducing infections among injecting drug users
Among people who inject drugs, the sharing of needles and 
syringes is the key risk factor for acquiring HCV infection, 
although there is also considerable evidence of a potentially 
high risk of infection associated with sharing drug-
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preparation equipment such as cookers, filters, swabs and 
water (Pouget et al., 2012). However, there is good evidence 
to show that retention in opioid substitution treatment 
reduces injection frequency (Gowing et al., 2008), and that 
it is most effective in reducing HCV transmission when 
used alongside interventions that support safer injection 
practices (Hagan et al., 2011). Two studies that examined 
the independent and combined effects of needle and syringe 
programmes and opioid substitution treatment on HCV 
incidence concluded that the combined effect of these two 
interventions resulted in the greatest reductions in HCV 
transmission (Turner et al., 2011; Van Den Berg et al., 2007).
However, modelling studies have been used to explore the 
potential effectiveness of different hepatitis C interventions, 
and these indicate that it may be difficult for opioid 
substitution treatment and high-coverage (1) needle and 
syringe programmes alone to substantially reduce the overall 
hepatitis C prevalence among people who inject drugs. For 
example, modelling the scale-up of both interventions for 
the United Kingdom (with 40 % baseline chronic hepatitis C 
prevalence among the target population) shows that they are 
only likely to lead to substantial reductions in the prevalence 
of chronic hepatitis C after 10 years, if both of these 
interventions cover 80 % or more of the injecting population 
(Vickerman et al., 2012). Such high coverage levels may be 
difficult to sustain over periods.  
I  Hepatitis C treatment as prevention 
Recent advances in hepatitis C treatment approaches, 
including the development of new molecules called direct-
acting antivirals (DAA) and the introduction of interferon-free 
treatment regimens show much promise (see box ‘Current 
treatment and new hepatitis C medicines), including the 
potential for treating hepatitis C among people who inject 
drugs. In this area, modelling studies suggest that hepatitis 
C treatment could play an important role in preventing the 
spread of the virus. A study by Martin et al. (2014) projecting 
the impact of current and scaled-up treatment on chronic 
HCV prevalence in a range of seven UK sites with varying 
prevalence levels indicated that an absolute reduction in 
hepatitis C prevalence of at least 15 % might be achieved over 
10 years as a result of treating 26 infections per year per  
1 000 people who inject drugs with relative reductions ranging 
from 12 % to 86 % after 10 years. 
I  Barriers to accessing hepatitis C treatment
In spite of recent improved treatment outcomes for hepatitis C 
patients, available data show treatment uptake continues to be 
very low among injecting drug users. The literature highlights 
a number of possible reasons for this. Service providers cite 
concerns around adherence, risk of exacerbation of psychiatric 
disorders and the potential for reinfection after treatment as 
reasons for not assessing or treating hepatitis C in injecting 
drug users (Edlin et al., 2001; Soriano et al., 2002). On the part 
of patients, the lack of access of people who inject drugs to 
testing still constitutes a key-barrier to entering a care pathway. 
In addition, poor knowledge about hepatitis C and treatment 
availability, the absence of noticeable symptoms (Grebely et 
al., 2011) and the perceived side-effects of treatment (Swan et 
al., 2010) are named as barriers for accessing hepatitis C care. 
Finally, until recently, current drug injecting was an exclusion 
criterion for receiving government-funded hepatitis C antiviral 
treatment in a number of European countries. This obstacle, 
however, is now being removed, with most clinical guidelines 
revised to allow for the treatment of hepatitis C in injecting drug 
users. 
I  Strategies to improve treatment and care
A number of the lessons learned in responding to the 
HIV epidemic can be transferred to reducing the spread 
of hepatitis C among people who inject drugs, including 
recognition of the importance of putting in place a set of 
comprehensive, coordinated and multidisciplinary responses. 
Advocacy groups in Europe have highlighted the need to 
develop HCV services. In particular, the need for strategies 
to reduce the burden of HCV among people who use drugs, 
including improved access to HCV testing, treatment and 
care services, and the scaling-up of community-based and 
harm reduction interventions. The enhancement of treatment 
uptake is important for people who inject drugs and effective 
treatment options need to be available and easily accessible 
for this population group. The co-location of hepatitis C 
treatment and opioid substitution treatment is likely to 
facilitate user access, and might also be linked with mental 
health care. Improving treatment adherence among people 
who inject drugs is another area where improvements can 
be made and the use of case management, support services 
(1 ) Where injecting drug users receive on average one or more sterile syringes for 
each injection reported.
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and provider education and training to improve health- and 
HCV-literacy among PWID and service providers are likely to 
enhance care.
I  Conclusion 
This analysis draws attention to the high levels of HCV 
infection among people who inject drugs, both as an urgent 
public health priority, and as a field that has recently seen 
major advances in medical interventions. If hepatitis C 
treatments for people who inject drugs are to be effective, 
they will need to be embedded in and delivered as part of a 
comprehensive package of interventions. An important area 
for future investigation will be to review the uptake of hepatitis 
C treatment among people who inject drugs, and identify and 
challenge any barriers that prevent them from receiving an 
adequate and equitable service. 
I  Facts and figures 
Hepatitis C is a liver disease caused by the hepatitis C 
virus (HCV)
The incubation period for hepatitis C ranges from as little 
as 2 weeks to 6 months
Following initial infection with HCV, approximately 80 % of 
people do not exhibit any symptoms 
In 25 % of liver cancer patients, the underlying cause is 
hepatitis C
Approximately 130–150 million people worldwide have 
chronic HCV infection (WHO, 2014)
Between 14 % and 84 % of injecting drug users in Europe 
are infected with HCV
About 75–85 % of newly infected individuals develop 
chronic disease and 60–70 % of those with chronic HCV 
infection develop chronic liver disease; 5–20 % develop 
cirrhosis and 1–5 % die from cirrhosis or liver cancer
I  Interactive element: video
Video: hepatitis C treatment among injecting drug users available on the EMCDDA 
website: emcdda.europa.eu/topics/pods/hepatitis-c-treatment
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The goal of HCV treatment is to achieve a sustained 
virological response (SVR), which is defined as 
undetectable HCV RNA six, and lately three, months 
after cessation of therapy, leading to HCV clearance 
(Wendt et al., 2014; Martinot-Peignoux et al., 2010). SVR 
corresponds to a definitive cure of HCV infection in more 
than 99 % of cases (Swain et al., 2010) and is associated 
with improved outcomes regarding HCV-related liver 
disease, including fibrosis, cirrhosis, cancer and death. 
Until recently, the standard hepatitis C treatment has been 
injectable pegylated interferon (PEG-INF) alpha (interferon 
is an immunomodulating protein that interferes with viral 
replication; in pegylated form it lasts longer in the body) 
combined with oral ribavirin (RBV), an antiviral medication, 
so-called PEG-INF-RBV therapy (PR).  However, treatment 
with interferon has several and even some life-threatening 
side effects and is poorly tolerated by some patients (WHO, 
2014; EASL, 2014a). 
Scientific advances have led to the development of new 
antiviral drugs for hepatitis C, which are much more 
effective, safer and better-tolerated than existing therapies. 
These therapies, known as oral directly acting antiviral 
agent (DAAs) therapies simplify hepatitis C treatment by 
significantly decreasing monitoring requirements and by 
increasing cure rates (WHO, 2014). Direct-acting antiviral 
agents target particular stages in the life cycle of the virus in 
order to prevent it replicating. 
There are two main areas of research in this field. The first 
is concerned with drugs or therapies, known as protease 
and polymerase inhibitors, which block particular enzymes 
crucial for the viral lifecycle. The second area is looking at 
drugs that interfere with the genetic structure of the virus. 
Research is currently being carried out into inhibitors that 
can interrupt the activity of the enzymes linked with the 
replication of the hepatitis C virus. The launch of first-
generation protease inhibitors in 2011 provided major 
advances for genotype 1 patients, the most common of the 
six HCV genotypes. Two first-wave, first-generation protease 
inhibitors, telaprevir and boceprevir were approved for 
use in combination with PR in patients infected with HCV 
genotype 1 and are recommended in clinical guidelines (e.g. 
NICE 2012a; 2012b; EASL 2014a). Treatment results show 
increased SVR rates by 30 % for naïve patients, and even 
more for treatment-experienced genotype 1 patients who 
were relapsers to previous PR treatment (Wendt et al., 2014; 
Bacon et al., 2011).   
But things are changing rapidly and there are many new 
hepatitis C medicines in the pipeline, often showing 
promising results in phase II and III clinical trials. New 
hepatitis C treatments have entered or are about to enter 
the markets, which improve on the older treatment regimes 
in a number of ways. They can be taken orally rather than 
injected; they are taken once a day rather than two times 
a day or more; the side effects of the medication are 
significantly reduced; treatment is of a shorter duration; and 
there are many fewer drug-drug interactions.
In January 2014 , sofosbuvir, an inhibitor that interrupts 
the activity of the enzyme polymerase, used for hepatitis 
C virus replication, became the first all oral treatment 
medication for hepatitis C in combination with ribavirin 
to be given marketing authorisation by the European 
Commission. This was followed by new triple-therapy 
options, allowing for short duration, interferon-free and 
ribavirin independent regimens for genotype 1 and 4 
patients by combining sofosbuvir with two other DAAs, 
which entered the market in May (simeprevir) and August 
2014 (daclatasvir) (EASL, 2014b). In November 2014, EU 
regulators granted authorization for a once-daily single 
tablet treatment regimen, combining sofosbuvir with 
ledipasvir, a highly potent anti-retroviral across genotypes. 
Depending on prior treatment history and cirrhosis status, 
duration of treatment is reduced to 12 to 24 weeks. The 
medication, indicated for genotypes 1 and 4 patients - 
including those with HIV co-infection - achieved SVR rates 
of 94 % to 95 % twelve weeks after completing therapy 
even without ribavirin (ION-I, ION-II and ION-III trials; see 
Medscape slideshow http://www.medscape.com/features/
slideshow/ion).  In January 2015, a so-called 3D all-oral 
combination of DAAs (paritaprevir/ritonavir-ombitasvir-
dasabuvir) that can be used with or without ribavirin was 
approved by the European Commission (paritaprevir-
ritonavir-ombitasvir-dasabuvir), adding another 12- to 
24-week treatment option for HCV genotype 1 patients.
Various combinations using DAAs showed high rates of 
sustained virological response (~95 %). Importantly, high 
cure rates were also demonstrated in patients with previous 
treatment failures, decompensated cirrhosis and hepatitis 
C recurrence after transplantation, making it clear that the 
interferon era is over (not so clear for ribavirin, which might 
still have a role in difficult-to-treat populations) (Lodoño et 
al., 2014). 
 
Current treatment and new hepatitis C medicines 
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Eliminating the need for interferon injections and with 
reduced treatment durations, it is hoped that the new 
regimens will both increase the uptake and facilitate the 
retention in treatment for people who inject drugs (PWID). 
Despite these outstanding developments, which have 
created high expectations of curing the disease in more 
than 90 % of patients, data from real-life cohorts evaluating 
the new antiviral combinations on a longer-term basis are 
still needed. Furthermore, the costs of antiviral medicines 
remain high – potentially presenting a barrier for individuals 
wishing to initiate or continue hepatitis C treatment. 
The possibility of developing a therapeutic vaccine, which 
would prevent the development of chronic HCV infection 
following repeated exposure, is feasible and being 
investigated, although a long way off at present, according a 
recent review (Grebely et al., 2012)
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